Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4
The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
Authors Tillmann HL
Published 8 August 2008 Volume 2008:4(4) Pages 797—802
Hans Ludger Tillmann
Medizinische Klinik und Poliklinik II, Universität Leipzig, Germany
Abstract: Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.
Keywords: adefovir, tenofovir, pradefovir, almefovir, antiviral therapy, hepatitis B
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.